Concord Biotech Ltd.

543960

Equity

ISIN INE338H01029 / Valor 128746036

Bombay Stock Exchange Ltd. (Mumbai) (2026-07-30)

INR 1,333.20+0.23%

Concord Biotech Ltd.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Concord Biotech Limited is an Ahmedabad-based biopharmaceutical company, founded in 2000 by Sudhir Vaid (Chairman & MD), a former director at Ranbaxy Laboratories. Led by CEO Ankur Vaid, the company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide. It was the first company in India and the second in the world to develop tacrolimus (an anti-immunosuppressant). Products span immunosuppressant, oncology, antifungal, antibacterial and anthelmintic therapy segments. Manufacturing facilities are at Dholka (near Ahmedabad; USFDA-approved) and Limbasi (Kheda district). In April 2026, the company acquired 100% of Celliimune Biotech for ₹66 lakh. Revenue ₹1,016 crore FY24; operating profit ₹466 crore FY24; net profit ₹308 crore FY24; 1,180 employees. Market capitalisation approximately ₹12,579 crore. Listed on both BSE and NSE (CONCORDBIO).

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-26.4%1Y

%3Y

%5Y

Performance

38.7%1Y

43.5%3Y

43.5%5Y

Volatility